{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:03:10Z","timestamp":1792134190457,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103011","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:28Z","timestamp":1783726228000},"page":"103011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The landscape and trajectory of global CRISPR therapeutics"],"prefix":"10.1016","volume":"37","author":[{"given":"Ceren","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Maria","family":"Formica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Della Pelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Gottenborg","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0131sra","family":"\u00c7avdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Lykke","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise","family":"Askou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"K\u00f6ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Jimenez-Mallebrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Cortijo","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Frasez","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus O.","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-6651","authenticated-orcid":false,"given":"Aylin","family":"Sendemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Benabdellah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeevkumar Raveendran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7759","authenticated-orcid":false,"given":"Yonglun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103011_bib1","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103011_bib2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103011_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103011_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103011_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","article-title":"DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing","volume":"37","author":"Xue","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.omtn.2026.103011_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103011_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2026.103011_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103011_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103011_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12032-022-01930-6","article-title":"Molecular and therapeutic effect of CRISPR in treating cancer","volume":"40","author":"Rodrigo","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omtn.2026.103011_bib11","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1038\/s41467-021-23576-0","article-title":"Enhancing CRISPR-Cas9 gRNA efficiency prediction by data integration and deep learning","volume":"12","author":"Xiang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103011_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for Improving HDR Efficiency","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2026.103011_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247603","article-title":"Systematic analysis of factors that improve homologous direct repair (HDR) efficiency in CRISPR\/Cas9 technique","volume":"16","author":"Di Stazio","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103011_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nbt.3481","article-title":"Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA","volume":"34","author":"Richardson","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103011_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98965-y","article-title":"Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair","volume":"11","author":"Schubert","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103011_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.103011_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA Base-Editing and Prime-Editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103011_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2217T to G\u2217C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103011_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103011_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01607-1","article-title":"High-efficiency TadA cytosine base editors for precise modelling of human disease variants","author":"Qin","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2026.103011_bib21","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1038\/s41467-025-65200-5","article-title":"Deep learning models simultaneously trained on multiple datasets improve base-editing activity prediction","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103011_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2020.05.037","article-title":"Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning","volume":"182","author":"Arbab","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103011_bib23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103011_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41592-020-0966-x","article-title":"An efficient KRAB domain for CRISPRi applications in human cells","volume":"17","author":"Alerasool","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2026.103011_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2026.103011_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","article-title":"Epigenome editing technologies for discovery and medicine","volume":"42","author":"McCutcheon","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103011_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/giy011","article-title":"Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases","volume":"7","author":"Lin","year":"2018","journal-title":"GigaScience"},{"key":"10.1016\/j.omtn.2026.103011_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","article-title":"Durable and efficient gene silencing in vivo by hit-and-run epigenome editing","volume":"627","author":"Cappelluti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103011_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103011_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-021-21188-2","article-title":"Programmable human histone phosphorylation and gene activation using a CRISPR\/Cas9-based chromatin kinase","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103011_bib31","doi-asserted-by":"crossref","first-page":"102457","DOI":"10.1016\/j.omtn.2025.102457","article-title":"Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group. Molecular therapy","volume":"36","author":"Cavazza","year":"2025","journal-title":"Nucleic acids"},{"key":"10.1016\/j.omtn.2026.103011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2026.103011_bib33","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","article-title":"Development and clinical translation of ex vivo gene therapy","volume":"20","author":"Wu","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.omtn.2026.103011_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.addr.2020.06.011","article-title":"Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases","volume":"168","author":"Yu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.103011_bib35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.omtn.2026.103011_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.amjmed.2023.12.018","article-title":"CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era","volume":"137","author":"Adashi","year":"2024","journal-title":"Am. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241246351","article-title":"Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review","volume":"33","author":"Rostami","year":"2024","journal-title":"Cell Transplant."},{"key":"10.1016\/j.omtn.2026.103011_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hum.2016.007","article-title":"Gene Therapy of the beta-Hemoglobinopathies by Lentiviral Transfer of the beta(A(T87Q))-Globin Gene","volume":"27","author":"Negre","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.103011_bib40","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib41","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2501277","article-title":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat beta-Thalassemia","volume":"394","author":"Frangoul","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa2415550","article-title":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"394","author":"Hanna","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib43","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2504835","article-title":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease","volume":"394","author":"Gupta","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41586-026-10342-9","article-title":"Clinical application of base editing for treating beta-thalassaemia","volume":"653","author":"Lai","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103011_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103011_bib46","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2026.103011_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-021-02076-5","article-title":"CRISPR\/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy","volume":"40","author":"Ghaffari","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103011_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112639","article-title":"CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtn.2026.103011_bib50","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103011_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.omtn.2026.103011_bib52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jnc.15233","article-title":"Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis","volume":"156","author":"Dohrn","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2026.103011_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib55","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Clinical practice. Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib56","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib57","article-title":"Clinical characteristics and current therapies for inherited retinal degenerations","volume":"5","author":"Sahel","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib58","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene Editing for CEP290-Associated Retinal Degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103011_bib59","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2026.103011_bib60","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2026.103011_bib61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/VHRM.S275739","article-title":"PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance","volume":"18","author":"Jia","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.omtn.2026.103011_bib62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2026.103011_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.omtn.2026.103011_bib64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/crispr.2024.0042","article-title":"Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative","volume":"7","author":"Rueda","year":"2024","journal-title":"CRISPR J."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:09:23Z","timestamp":1788880163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126001824"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103011","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape and trajectory of global CRISPR therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103011"}}